TP53 and plasma cell myeloma: Of note, we show PBOX-15 activity in myeloma cells isolated from patients with poor clinical prognosis: sample no. 5, which was obtained from a lenalidomide-refractory patient who had relapsed following allogenic HSCT, and sample no. 4, harbouring a 17p deletion associated with loss of p53 expression and aggressive disease (Yeung and Chang, 2008).